Clinical trial Recruiting at 1 site Interventional Ages 14 to 18

E-cigarette Cessation for Hispanic/Latino Teens in Florida

Official title: Developing an E-Cigarette Cessation Intervention for Hispanic/Latina(o) Youth in Florida

Run by Florida International University · NCT07192601 · Data updated 2026-11-12

This project tests a six-session, CBT-based e-cigarette cessation program tailored for Hispanic/Latino high school students to see if it helps reduce vaping use.

Quick facts

Study typeInterventional
Ages14 Years to 18 Years
SexAll
Enrollment120 (estimated)
SponsorFlorida International University
Academic / other
Locations1 site (Miami, Florida)
StatusRecruiting
StartedOctober 26, 2026
Main results expectedDecember 31, 2027
Study endsApril 30, 2028
Registry record updatedOctober 28, 2026
Trial IDNCT07192601 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are English-fluent Hispanic/Latino high school students aged 14-18 who currently use e-cigarettes at least weekly or 4+ times in the past month and are not enrolled in other cessation programs.

Probably not a fit

Young people who do not identify as Hispanic/Latino, do not currently vape, or have significant psychiatric conditions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study develops and pilots the BReATHE cessation program for Hispanic/Latino high school students who vape. It uses focus groups and a community advisory board to shape the intervention, which consists of six in-person group sessions and a baseline assessment. The trial will enroll about 120 participants to assess feasibility and early signals of reduced e-cigarette use. Eligibility focuses on high school students aged 14-18 who identify as Hispanic/Latino, are fluent in English, and currently vape. Exclusion criteria include serious psychiatric conditions, current involvement in another cessation program, or language barriers that would impede procedures.

Why it matters

Potential benefit: If successful, the program could provide a culturally tailored, evidence-informed option to help Hispanic/Latino youth reduce or stop vaping.

How similar studies have gone: Previous CBT-based cessation approaches have shown promise in adolescents, but this program is specifically tailored for Hispanic/Latino youth, a group with less prior testing.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Enrolled in high school or 14-18 years old
* Fluent in English
* Identify as being of Hispanic/Latino origin
* Report current use of e-cigarettes (i.e., used ≥ 4x in the past month or at least 1x per week in the past month)

Exclusion Criteria:

* Having a history of severe psychiatric conditions (e.g., bipolar disorder, schizophrenia, psychosis, or schizoaffective disorder)
* Currently enrolled in or planning on enrolling in another e-cigarette and/or tobacco cessation intervention
* Having potential difficulties comprehending study procedures (e.g., not able to speak/write in English, have a severe learning disability or other neurodevelopmental disorders)

Where it's running

  • FIU Center for Children and Families
    Miami, Florida, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Parents Helping Parents for Youth Vaping Cessation

    This project tests whether a parent-supported program can help teens quit vaping by pairing trained parent coaches with families.

    Recruiting University of Nebraska · Omaha, Nebraska · NCT07207850

  • Personalized brain-targeted TMS for smoking cessation

    A personalized brain-guided Transcranial Magnetic Stimulation (TMS) approach is tested against a standard TMS method to see if it better changes reward brain activity and reduces cravings and smoking in adults with tobacco use disorder.

    Recruiting Rutgers, The State University of New Jersey · Newark, New Jersey · NCT07812753

  • Multilevel program to increase LDCT lung cancer screening and help African American smokers quit

    This program will try combining low-dose CT screening with culturally tailored smoking-cessation support to help African American smokers who are eligible for LDCT quit and get screened.

    Recruiting at 2 sites Louisiana State University Health Sciences Center in New Orleans · New Orleans, Louisiana and 1 other locations · NCT07576595

  • TUBSIS 2.0 — an online program to help adults reduce or quit smoking and vaping

    This program tests whether a free, anonymous, 4-week web-based course using mindfulness, self-compassion, and behavior-change techniques helps German-, English-, and Turkish-speaking adults who smoke or vape reduce or quit tobacco.

    Recruiting University of Zurich · Zurich · NCT07568483

  • Impact of Menthol vs. Non-Menthol Cigarettes on Abuse Liability

    This study tests whether menthol cigarettes have different abuse potential than non-menthol cigarettes in menthol cigarette users, using a within-subject design across lab sessions and daily diaries.

    Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07564648

  • Social media support groups to help teens and young adults quit vaping

    This pilot tries a social-media group program called the Quit the Hit Toolkit to help adolescents and young adults who vape stop using nicotine.

    Recruiting University of California, San Francisco · San Francisco, California · NCT07540780

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.